5/31
10:00 am
psnl
Tempus Announces the Clinical Launch of its MRD Testing Portfolio [Yahoo! Finance]
Medium
Report
Tempus Announces the Clinical Launch of its MRD Testing Portfolio [Yahoo! Finance]
5/31
09:19 am
psnl
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus [Yahoo! Finance]
Low
Report
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus [Yahoo! Finance]
5/31
09:05 am
psnl
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
Medium
Report
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
5/22
09:14 am
psnl
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024 [Yahoo! Finance]
High
Report
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024 [Yahoo! Finance]
5/22
09:05 am
psnl
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
High
Report
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
5/17
04:05 pm
psnl
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/9
12:36 pm
psnl
Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
08:18 am
psnl
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
Low
Report
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
5/9
07:53 am
psnl
Personalis First Quarter 2024 Earnings: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023) [Yahoo! Finance]
Low
Report
Personalis First Quarter 2024 Earnings: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023) [Yahoo! Finance]
5/8
04:58 pm
psnl
Personalis Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Personalis Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/8
04:31 pm
psnl
Personalis: Q1 Earnings Snapshot [Yahoo! Finance]
Low
Report
Personalis: Q1 Earnings Snapshot [Yahoo! Finance]
5/8
04:01 pm
psnl
Personalis Reports First Quarter 2024 Financial Results
Medium
Report
Personalis Reports First Quarter 2024 Financial Results
4/30
12:10 pm
psnl
Personalis, Inc. (NASDAQ: PSNL) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $4.00 price target on the stock.
Low
Report
Personalis, Inc. (NASDAQ: PSNL) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $4.00 price target on the stock.
4/24
04:01 pm
psnl
Personalis to Announce First Quarter 2024 Financial Results
Medium
Report
Personalis to Announce First Quarter 2024 Financial Results
4/11
08:26 am
psnl
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
Low
Report
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $3.50 price target on the stock.
3/28
04:01 pm
psnl
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Medium
Report
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
3/28
09:28 am
psnl
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
Low
Report
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
3/28
09:00 am
psnl
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Low
Report
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
3/26
09:19 am
psnl
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring [Yahoo! Finance]
Medium
Report
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring [Yahoo! Finance]
3/26
09:00 am
psnl
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
Low
Report
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
3/19
04:43 pm
psnl
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)